| Literature DB >> 27197769 |
Venkatesh Gopalan1, Navin Michael2, Seigo Ishino3, Swee Shean Lee1, Adonsia Yating Yang4, K N Bhanu Prakash1, Jadegoud Yaligar1, Suresh Anand Sadananthan2, Manami Kaneko3, Zhihong Zhou4, Yoshinori Satomi3, Megumi Hirayama3, Hidenori Kamiguchi3, Bin Zhu4, Takashi Horiguchi5, Tomoyuki Nishimoto3, S Sendhil Velan1.
Abstract
Both exercise and calorie restriction interventions have been recommended for inducing weight-loss in obese states. However, there is conflicting evidence on their relative benefits for metabolic health and insulin sensitivity. This study seeks to evaluate the differential effects of the two interventions on fat mobilization, fat metabolism, and insulin sensitivity in diet-induced obese animal models. After 4 months of ad libitum high fat diet feeding, 35 male Fischer F344 rats were grouped (n = 7 per cohort) into sedentary control (CON), exercise once a day (EX1), exercise twice a day (EX2), 15% calorie restriction (CR1) and 30% calorie restriction (CR2) cohorts. Interventions were carried out over a 4-week period. We found elevated hepatic and muscle long chain acylcarnitines with both exercise and calorie restriction, and a positive association between hepatic long chain acylcarnitines and insulin sensitivity in the pooled cohort. Our result suggests that long chain acylcarnitines may not indicate incomplete fat oxidation in weight loss interventions. Calorie restriction was found to be more effective than exercise in reducing body weight. Exercise, on the other hand, was more effective in reducing adipose depots and muscle triglycerides, favorably altering muscle/liver desaturase activity and improving insulin sensitivity.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27197769 PMCID: PMC4873816 DOI: 10.1038/srep26445
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline measurements (post 4 months of ad libitum HFD feeding) of body weight, adipose depots, ectopic fat and serum metabolic parameters (mean ± sd, P < 0.05 in bold).
| Measurements/Cohort | CR1(N = 7) | CR2(N = 7) | EX1(N = 7) | EX2(N = 7) | CON(N = 7) | P-value |
|---|---|---|---|---|---|---|
| Triglycerides (mg/dL) | 462.86 ± 118.23 | 507.00 ± 144.03 | 454.29 ± 79.71 | 501.43 ± 174.60 | 433.71 ± 100.49 | 0.790 |
| Glucose (mg/dL) | 176.57 ± 25.94 | 165.29 ± 13.39 | 164.43 ± 17.56 | 182.14 ± 19.36 | 156.57 ± 13.66 | 0.102 |
| Insulin (ng/mL) | 5.66 ± 2.01 | 4.30 ± 1.18 | 4.62 ± 0.58 | 4.89 ± 1.29 | 4.60 ± 0.88 | 0.360 |
| QUICKI | 0.231 ± 0.011 | 0.238 ± 0.008 | 0.236 ± 0.004 | 0.232 ± 0.005 | 0.237 ± 0.003 | 0.248 |
| Leptin (ng/mL) | 26.67 ± 4.77 | 24.50 ± 6.94 | 22.76 ± 3.03 | 26.29 ± 7.44 | 22.09 ± 4.46 | 0.452 |
| Body weight (g) | 363.72 ± 4.63 | 368.46 ± 6.44 | 364.09 ± 7.12 | 365.75 ± 10.99 | 362.86 ± 5.64 | 0.634 |
| Intrahepatic lipid | 26.79 ± 4.36 | 3.99 | 25.15 ± 2.84 | 25.48 ± 4.71 | 27.98 ± 5.60 | 0.764 |
| Intramyocellular lipids | 1.21 ± 1.25 | 1.34 ± 0.54 | 1.13 ± 0.42 | 0.96 ± 0.36 | 1.08 ± 0.32 | 0.873 |
| SAT (mm3) | 474.21 ± 166.86 | 91.18 | 281.41 ± 86.40 | 442.26 ± 108.37 | 351.15 ± 218.11 | 0.128 |
| VAT (mm3) | 10668.97 ± 1031.15 | 10231.29 ± 711.94 | 9712.57 ± 997.59 | 10456.37 ± 836.31 | 9222.44 ± 1053.02 |
#Intrahepatic lipid was calculated by ratio of (Fat/(Fat + H2O))*100.
$Intramyocellular lipid = Intramyocellular lipid/total creatine.
@QUICKI = 1/(log(Fasting Glucose (mg/dL)) + log(Fasting Insulin (μU/mL)).
Figure 1Body weight curves for different groups during the 28 days of intervention period for control, exercise and calorie restriction groups.
Post-intervention measurements of body weight, adipose depots, ectopic fat and serum metabolic parameters, daily food intake and daily dietary calorie deficit during 28-day intervention (mean ± sd, P < 0.05 in bold).
| Measurements/Cohort | CR1(N = 7) | CR2(N = 7) | EX1(N = 7) | EX2(N = 7) | CON(N = 7) | P-value |
|---|---|---|---|---|---|---|
| Triglycerides (mg/dL) | 459.43 ± 76.22 | 424.71 ± 69.78 | 498.43 ± 142.39 | 563.14 ± 248.65 | 473.14 ± 56.04 | 0.435 |
| Glucose (mg/dL) | 158.93 ± 15.32 | 163.23 ± 19.25 | 164.71 ± 24.69 | 160.03 ± 21.34 | 158.83 ± 9.61 | 0.965 |
| Insulin (ng/mL) | 3.57 ± 1.35 | 3.30 ± 0.76 | 2.86 ± 0.57 | 2.74 ± 1.29 | 3.91 ± 0.73 | 0.178 |
| QUICKI | 0.244 ± 0.009 | 0.245 ± 0.005 | 0.248 ± 0.006 | 0.252 ± 0.013 | 0.241 ± 0.005 | 0.126 |
| Leptin (ng/mL) | 26.99 ± 4.92 | 20.77 ± 6.90 | 17.73 ± 2.54 | 14.74 ± 3.67 | 34.34 ± 6.53 | |
| Body weight (g) | 360.86 ± 7.97 | 344.71 ± 6.60 | 363.43 ± 10.85 | 360.86 ± 7.97 | 384.44 ± 7.41 | |
| Intrahepatic lipid | 18.24 ± 5.27 | 14.16 ± 5.31 | 19.02 ± 2.92 | 16.94 ± 4.84 | 29.06 ± 11.24 | |
| Intramyocellular lipids | 1.02 ± 0.28 | 1.07 ± 0.33 | 1.14 ± 0.27 | 1.21 ± 0.35 | 1.06 ± 0.19 | 0.755 |
| SAT (mm3) | 448.85 ± 179.71 | 290.80 ± 133.73 | 287.39 ± 61.14 | 207.55 ± 37.81 | 494.90 ± 113.62 | |
| VAT (mm3) | 10410.44 ± 276.94 | 9333.13 ± 1103.97 | 9188.80 ± 627.74 | 8278.41 ± 1054.54 | 10610.23 ± 632.14 | |
| Daily food intake (g) | 11.57 ± 0.51 | 9.64 ± 0.42 | 12.83 ± 1.05 | 12.77 ± 0.80 | 13.72 ± 0.47 | |
| Dietary calorie deficit | 10.10 | 19.18 | 4.18 | 4.46 | – | – |
#Intrahepatic lipid was calculated by ratio of (Fat/(Fat + H2O))*100.
$Intramyocellular lipid = Intramyocellular lipid/total creatine.
*Dietary calorie deficits evaluated from daily food intake when compared to control.
@QUICKI = 1/(log(Fasting Glucose (mg/dL)) + log(Fasting Insulin (μU/mL)).
Glass’s ∆ effect size of interventions with respect to the control, for serum metabolic parameters, body weight, adiposity, adipose depot volumes, ectopic fat and tibialis muscle weight and triglycerides (*small effect (∆ ≥ 0.2), **moderate effect (∆ ≥ 0.5), ***large effect (∆ ≥ 0.8)).
| Measurement | Cohort | |||
|---|---|---|---|---|
| CR1(N = 7) | CR2(N = 7) | EX1(N = 7) | EX2(N = 7) | |
| Triglycerides (mg/dL) | −0.24* | −0.86*** | 0.45* | 1.61*** |
| Glucose (mg/dL) | 0.01 | 0.46* | 0.61** | 0.12 |
| Insulin (ng/mL) | −0.47* | −0.84*** | −1.44*** | −1.60*** |
| QUICKI | 0.63** | 0.71** | 1.38*** | 2.13*** |
| Leptin (ng/mL) | −1.13*** | −2.08*** | −2.54*** | −3.00*** |
| Body weight (g) | −3.18*** | −5.37*** | −2.84*** | −3.18*** |
| % body fat | −1.16*** | −2.73*** | −3.82*** | −5.62*** |
| Intrahepatic lipid | −0.96*** | −1.33*** | −0.89*** | −1.08*** |
| Intramyocellular lipids | −0.19 | 0.07 | 0.41* | 0.83*** |
| SAT (mm | −0.41* | −1.80*** | −1.83*** | −2.53*** |
| VAT (mm | −0.32* | −2.02*** | −2.25*** | −3.69*** |
| Tibialis weight (mg) | −0.35* | 0.15 | 1.62*** | 1.84*** |
| Tibialis triglycerides (mg/g tissue) | −0.43* | −0.35* | −0.81*** | −0.71** |
#Intrahepatic lipid was calculated by ratio of (Fat/(Fat + H2O))*100.
$Intramyocellular lipid = Intramyocellular lipid/total creatine.
@QUICKI = 1/(log(Fasting Glucose (mg/dL)) + log(Fasting Insulin (μU/mL)).
Glass’s ∆ effect size of interventions with respect to the control for muscle and liver desaturase indices (*small effect (∆ ≥ 0.2), **moderate effect (∆ ≥ 0.5), ***large effect (∆ ≥ 0.8)).
| Measurement | Cohort | |||
|---|---|---|---|---|
| CR1(N = 7) | CR2(N = 7) | EX1(N = 7) | EX2(N = 7) | |
| Muscle SCD16 | −0.90*** | −0.96*** | −1.04*** | −1.47*** |
| Muscle SCD18 | −0.91*** | −0.44* | −0.67** | −1.10*** |
| Muscle D6D | −0.96*** | −1.18*** | −1.47*** | −1.39*** |
| Muscle D5D | 1.01*** | 1.49*** | 0.95*** | 1.82*** |
| Liver SCD16 | −0.04 | −1.26*** | −1.05*** | −1.54*** |
| Liver SCD18 | 0.03 | −0.19 | 0.18 | −0.03 |
| Liver D6D | −0.68** | −1.01*** | −2.28*** | −2.37*** |
| Liver D5D | 1.33*** | 3.50*** | 3.06*** | 3.25*** |
Glass’s ∆ effect size of interventions with respect to the control for muscle and liver acylcarnitines (*small effect (∆ ≥ 0.2), **moderate effect (∆ ≥ 0.5), ***large effect (∆ ≥ 0.8)).
| Measurement | Cohort | |||
|---|---|---|---|---|
| CR1(N = 7) | CR2(N = 7) | EX1(N = 7) | EX2(N = 7) | |
| Liver AC C0 | 0.72** | 0.72** | 0.51** | 0.44* |
| Liver AC C2 | −0.08 | 0.11 | 0.60** | −0.13 |
| Liver AC C16:0 | 0.43* | −0.02 | 0.96*** | 0.33* |
| Liver AC C18:0 | 0.28* | −0.01 | 2.20*** | 1.11*** |
| Liver AC C18:1 | 0.40* | −0.05 | 1.51*** | 0.68** |
| Muscle AC C0 | 0.77** | 0.65** | 1.20*** | 0.45* |
| Muscle AC C2 | 0.04 | −0.25* | 0.05 | −0.56** |
| Muscle AC C4-OH | −0.45* | −0.60** | −0.20* | −1.00*** |
| Muscle AC C16:0 | 0.42* | 0.01 | 0.15 | 0.52** |
| Muscle AC C18:0 | 0.47* | 0.30* | 0.22* | 0.72** |
| Muscle AC C18:1 | 0.40* | −0.01 | 0.21* | 0.40* |
Association (Pearson r) between % body fat, insulin sensitivity, IHL, IMCL, adipose depots, muscle and liver acylcarnitines and muscle and liver desaturase indices obtained from the post-measurements in the pooled cohort (**P < 0.01 and *P < 0.05 in bold).
| % Body fat | QUICKI | IHL | IMCL | |
|---|---|---|---|---|
| Insulin sensitivity | 0.17 | |||
| Leptin | −0.23 | |||
| SAT | −0.32 | −0.18 | ||
| VAT | −0.26 | |||
| IHL | 1 | −0.04 | ||
| IMCL | −0.24 | 0.18 | −0.04 | 1 |
| Muscle AC C4-OH | 0.32 | −0.17 | 0.28 | 0.09 |
| Muscle AC C0 | 0.02 | 0.06 | −0.01 | −0.15 |
| Muscle AC C18:0 | −0.11 | 0.11 | −0.17 | |
| Muscle AC C16:0 | −0.03 | 0.08 | −0.13 | |
| Muscle AC C18:1 | −0.01 | 0.05 | −0.10 | |
| Muscle SCD16 | −0.29 | |||
| Muscle D6D | −0.29 | |||
| Muscle D5D | 0.23 | 0.21 | ||
| Liver SCD16 | −0.26 | |||
| Liver D6D | −0.41 | 0.38 | −0.32 | |
| Liver D5D | 0.08 | |||
| Liver AC C0 | 0.12 | 0.12 | −0.05 | −0.14 |
| Liver AC C16:0 | −0.18 | −0.14 | 0.20 | |
| Liver AC C18:0 | −0.38 | −0.14 | 0.27 | |
| Liver AC C18:1 | −0.28 | −0.20 | 0.19 |
@QUICKI = 1/(log(Fasting Glucose (mg/dL)) + log(Fasting Insulin (μU/mL)).